Clinical Trials Search at Vanderbilt-Ingram Cancer Center

This study evaluates the general physical, emotional, and sexual function in women undergoing a radical cystectomy for bladder cancer. A radical cystectomy is a surgical procedure that involves the removal of the bladder, uterus, ovaries, fallopian tubes, and part of the vagina. This may affect sexual function in women. This study seeks to understand how radical cystectomy alters sexual function and well-being, and what factors may affect this change.

The goal of this clinical study is to learn more about the long-term safety, effectiveness
and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel,
KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored
interventional studies.

In this observational study researcher want to learn more about the effectiveness of drug
VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use
in patients with TRK fusion cancer which is locally advanced or spread from the place where
it started to other places in the body. TRK fusion cancer is a term used to describe a
variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic
Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or
fuses, with a different gene. This joining results in the activation of certain proteins (TRK
fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an
approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult
and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the
decision to treat their disease with VITRAKVI has been made by their treating physicians.
During the study, patients' medical information such as treatment information with VITRAKVI,
other medication or treatments, changes in disease status and other health signs and symptoms
will be collected within the normal medical care by the treating doctor. Participants will be
observed over a period from 24 to 60 months.

This study assesses whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy. Studying samples of blood and urine from patients with kidney cancer that has spread to other places in the body (metastatic) in the laboratory may help doctors predict how well patients will respond to treatment.

This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.

To compare donors to their non-donor counterparts and healthy controls as well as to generate
trajectory classes based on longitudinal patterns of donor HRQoL and identify predictors of
poor donor HRQoL.

The purpose of this study is to collect long term safety data in subjects who are continuing
to derive clinical benefit from treatment with Enzalutamide from the subjects participation
in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study)
which has completed, at a minimum, the primary analysis or the study specified evaluation
period.

This phase II trial tests whether designing radiation to avoid bone marrow in the spine (vertebral bone marrow) leads to less reduction of white blood cell counts (lymphopenia) in patients with lung cancer. This sparing technique could lead to better disease control and outcome.

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and
pharmacodynamics of INCB099318 in select solid tumors.

This clinical trial will evaluate DS-6000a in participants with advanced renal cell carcinoma
(RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the
recommended dose of DS-6000a that can be given safely to participants, assess the side
effects of DS-6000a, and evaluate the effectiveness of DS-6000a.